Asif Ali - 12 Mar 2025 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
Chief Financial Officer
Signature
/s/ Matthew Gosling, Attorney-in-Fact for Asif Ali
Issuer symbol
PTGX
Transactions as of
12 Mar 2025
Net transactions value
-$1,091,390
Form type
4
Filing time
14 Mar 2025, 18:20:46 UTC
Previous filing
17 Jan 2025
Next filing
23 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Options Exercise $185,021 +15,203 +24% $12.17 78,024 12 Mar 2025 Direct
transaction PTGX Common Stock Options Exercise $186,143 +9,700 +12% $19.19 87,724 12 Mar 2025 Direct
transaction PTGX Common Stock Sale $1,462,553 -24,903 -28% $58.73 62,821 12 Mar 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTGX Stock Option (right to buy) Options Exercise $0 -15,203 -33% $0.000000 30,547 12 Mar 2025 Common Stock 15,203 $12.17 Direct F2
transaction PTGX Stock Option (right to buy) Options Exercise $0 -9,700 -13% $0.000000 66,800 12 Mar 2025 Common Stock 9,700 $19.19 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $58.12 to $59.235. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F2 The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer.
F3 The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer.